Myocardial Injury in One Third of COVID-19 Patients

Roughly one third of patients hospitalized for COVID-19 have some degree of myocardial injury and this comes hand in hand with increased mortality compared against patients with no troponin elevation. 

Manejo de los infartos durante la pandemia de Covid-19

Even mild forms of myocardial injury, such as 0.03 to 0.09 ng/mL troponin elevation, is associated with close to 100% increase in mortality (HR: 1.75; CI 95% 1.37-2.24).

In patients with greater injury (troponins over 0.09 ng/mL) mortality increases over 200% (HR 3.03; CI 95% 2.42-3.80).

This recent observational study soon to be published in JACC included 3069 patients diagnosed with COVID-19, hospitalized in New York.

The aim of this study was to better understand the prevalence of these troponin elevation and its impact on prognosis. 


Read also: Estimating the Risk of Infection for Healthcare Personnel.


Over 90% of patients were measured at least once for troponin-I elevation within 24hrs of admission. 455 of these showed mild elevation (0.03-0.09 ng/mL) and 530 significant elevation (> 0.09 ng/mL). 

Over one third of patients with significant elevation had previously been diagnosed with CAD. Atrial fibrillation and cardiac failure were also prevalent among patients with significant troponin-I elevation. 

The older the patient, the higher the body mass index and disease severity, the higher the mortality rate. After adjusting for covariables, troponin elevation continued to be a clear indicator of worse prognosis. 


Read also: Priorities in the Cath Lab to Escape COVID-19 Tsunami.


One of the limitations to this study was that other than troponin concentration no other tests were carried out, not even a 12-derivation electrocardiogram.      

With this information, we can conclude that troponin elevation is a prognosis marker, though it is hard to speculate about its etiology. 

It could be due to the cytokine storm or because of other acute phase reactants; it might also be the direct impact of the virus as myocarditis, or a non-ischemic myocardial injury due to the demand/offer imbalance, or a common acute coronary syndrome triggered by the inflammatory condition.


Read also: Covid-19 and Unaccounted Collateral Damage.


The COVID-19 pandemic history is being written and we are learning as we go. 

Original Title: Prevalence and impact of myocardial injury in patients hospitalized with COVID-19 infection.

Reference: Lala A et al. J Am Coll Cardiol. 2020; Epub ahead of print. doi: 10.1101/2020.04.20.20072702.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

AHA 2025 | VESALIUS-CV: Evolocumab in High-Cardiovascular-Risk Patients Without Prior MI or Stroke

LDL cholesterol is a well-established factor for cardiovascular disease. Therapy with PCSK9 inhibitors, including evolocumab, has been shown to reduce the risk of cardiovascular...

AHA 2025 | TUXEDO-2: Post-PCI Antiplatelet Management in Diabetic Patients with Multivessel Disease — Ticagrelor or Prasugrel?

Choosing the optimal P2Y12 inhibitor for diabetic patients with multivessel coronary artery disease undergoing percutaneous coronary intervention (PCI) remains a major clinical challenge. These...

AHA 2025 | DECAF: Coffee Consumption vs. Abstinence in Patients with Atrial Fibrillation: Recurrence or Myth?

The link between coffee consumption and arrhythmia has been met with contradicting recommendations. It is widely believed that caffeine could trigger atrial fibrillation (AF)...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Atrial Fibrillation After Percutaneous Patent Foramen Ovale Closure: Cohort Study with Continuous Implantable Cardiac Monitoring

Atrial fibrillation (AF) is a recognized complication following percutaneous closure of a patent foramen ovale (PFO), with reported incidences of up to 30% during...

Impact of Baseline Systolic Blood Pressure on Blood Pressure Changes Following Renal Denervation

Renal denervation (RDN) is a guideline-recommended therapy to reduce blood pressure in patients with uncontrolled hypertension, although uncertainties remain regarding which factors best predict...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...